HN 2401
Alternative Names: HN-2401Latest Information Update: 31 Mar 2025
At a glance
- Originator Shenzhen MagicRNA Biotechnology
- Class CAR-T cell therapies; Lipids; RNA
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 23 Mar 2025 Early research in Multiple sclerosis in China (Parenteral), before March 2025 (Shenzhen MagicRNA Biotechnology Pipeline, March 2025).
- 23 Mar 2025 Early research in Rheumatoid arthritis in China (Parenteral) before March 2025 (Shenzhen MagicRNA Biotechnology Pipeline, March 2025).